Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Trinity Biotech Plc's Competitiveness

Name: Trinity Biotech Plc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Trinity Biotech Plc (TRIB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

Competitors Tracked

Publicly traded peers

Peer Group Market Share

100.00 %

vs 100.00 % a year ago

Revenue Growth Y/Y

-28.87 %

Q4 2025

Net Margin

-85.36 %

Q4 2025

Key Findings: Trinity Biotech Plc vs Its Competitors

TTM: Trailing 12-month revenue of 44M vs -M combined for tracked competitors (100.0% combined share).
Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Scale: Trinity Biotech Plc ranks #17 of 19 companies by market capitalization in the In Vitro & In Vivo Diagnostic Substances industry, holding 0.0% of industry market cap.
Peer revenue share: Trinity Biotech Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

TRIB Sales vs. its Competitors, Q4 2025

Trinity Biotech Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/TRIB/competitors                    

                        https://api.csimarket.com/api/v1/companies/TRIB/relationships                    

                        https://api.csimarket.com/api/v1/companies/TRIB/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -28.9% for Trinity Biotech Plc. Trinity Biotech Plc's share of combined industry revenue moved from 1.84% to 1.28%, a loss of 0.56 percentage points.

Trinity Biotech Plc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Trinity Biotech Plc	No	No	No	Yes
Similar-Size Competitors (6)
Similar Growth & Profitability (8)	0.00 % (0 of 8)	25.00 % (2 of 8)	25.00 % (2 of 8)	14.30 % (1 of 7)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

TRIB Stock Performance relative to its Competitors

TRIB Competitors (weighted) Percent change over the selected range

Trinity Biotech Plc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(0 of 4)

Similar Growth & Profitability
(2 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Trinity Biotech Plc	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (4)	40.4%	63.2%
Similar Growth & Profitability (5)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Trinity Biotech Plc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

TRIB Stock Performance relative to Similar-Size Competitors

TRIB Similar-Size Competitors (equal-weighted, 6) Percent change over the selected range

TRIB Stock Performance relative to Similar Growth & Profitability Competitors

TRIB Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Trinity Biotech Plc's Comment on Competition and Industry Peers

The Premier Hb9210 platform is positioned in the global HbA1c testing market and holds certification from the International Federation of Clinical Chemistry. The company also markets the Premier Resolution, a CE-cleared haemoglobinopathy analyzer available in the EU, which detects genetic disorders including sickle-cell disease and thalassemia. The Premier Resolution has been launched in Europe and the Middle East. The company faces regulatory risks such as potential litigation under healthcare reimbursement laws, consumer protection statutes, the federal Lanham Act, and FDA enforcement actions concerning promotional materials and sales activities.